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The long-term effects of bariatric surgery on non-alcoholic steatohepatitis (NASH),
focusing on liver injury and hepatocyte apoptosis, are not well-established. We here
performed a longitudinal study with paired liver biopsies of nine morbidly obese women
(median BMI: 42 [38.7; 45.1] kg/m2) with NASH with a median follow-up of 55 [44; 75]
months after laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery. LRYGB surgery
was associated with significant weight loss (median BMI loss −13.7 [−16.4; −9.5]
kg/m2), improved hepatic steatosis in all patients (55.5% with total resolution), and
resolution of hepatic inflammation and hepatocyte ballooning in 100 and 88.8% of cases,
respectively. Alanine aminotransferase levels dropped to normal values while hepatic
activated cleaved caspase-3 levels strongly decreased after a median follow-up of 55
months. Hepatocyte apoptosis, as evaluated by serum caspase-generated keratin-18
fragment, improved within the first year following LRYGB and these improvements
persisted for at least 55 months. LRYGB in morbidly obese patients with NASH is
thus associated with a long-lasting beneficial impact on hepatic steatohepatitis and
hepatocyte death.
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INTRODUCTION
Obesity represents a major health burden, as it is associated with a growing number of
comorbidities (Must et al., 1999; Stevens et al., 2012). As the prevalence of obesity increases, so
does the prevalence of non-alcoholic fatty liver disease (NAFLD), which is now the leading cause
of chronic liver disease in the Western world (Younossi et al., 2011, 2016; Setiawan et al., 2016).
NAFLD includes a spectrum of liver abnormalities, ranging from simple steatosis to non-alcoholic
steatohepatitis (NASH) and to liver cirrhosis, eventually leading to hepatocellular carcinoma (Tran
and Gual, 2013; Yeh and Brunt, 2014). Regarding NASH, which is characterized by the presence
of liver inflammation and injury (hepatocyte ballooning and apoptosis), recent reports indicate
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that it is the second most common indication for liver
transplantation in the United States (Wong et al., 2015). To
counter the obesity epidemic, bariatric surgery has emerged as
the only therapeutic treatment that results in long-term weight
loss and improvement or resolution of most obesity-related
comorbidities (Mitka, 2012; Schauer et al., 2014). However,
evidence of the long-term efficacy of bariatric surgery against
NASH is not well-established. A recent report, including a cohort
of 109 morbidly obese patients with biopsy-proven NASH, has
shown that bariatric surgery induced the disappearance of NASH
in nearly 85% of patients and reduced the pathological features
of the disease after 12 months of follow-up (Lassailly et al.,
2015). Other results reported in the literature are more disparate
and focus on various liver complications (mainly steatosis and
fibrosis) with differing bariatric procedures and with a follow-
up never exceeding 24 months (Silverman et al., 1995; Clark
et al., 2005; Mattar et al., 2005; Mottin et al., 2005; Barker
et al., 2006; Csendes et al., 2006; de Almeida et al., 2006; Klein
et al., 2006; Furuya et al., 2007; Liu et al., 2007; Mathurin et al.,
2009; Chavez-Tapia et al., 2010). In this study, we evaluated
the long-term effects (median follow-up biopsy at 55 months)
of laparoscopic Roux-en-Y gastric bypass (LRYGB) surgery on
hepatic NASH features and liver injury (mainly hepatocyte
apoptosis) in morbidly obese women with biopsy-proven NASH
at the time of the surgery.
MATERIALS AND METHODS
Study Design
Five hundred and sixty-eight consecutive severely and morbidly
obese patients, referred for bariatric surgery, were included
between December 2002 and December 2009. The study
protocol was performed according to the French legislation
regarding Ethics and Human Research and was approved by the
local Ethics Committee (Huriet-Serusclat law, DGS 2003/0395).
Written informed consent was obtained from all patients. All
patients met the 1992 NIH Consensus Conference guidelines for
gastrointestinal surgery for obesity. These patients underwent
bariatric surgery at the Department of Digestive Surgery and
Liver Transplantation of the University of Nice (France). All
patients had a preoperative work-up (repeated at 6 and 12
months after surgery) and underwent a wedge-liver biopsy at
the time of surgery. A second liver biopsy and a concomitant
diagnostic work-up were offered to patients who underwent a
LRYGB, and who initially presented with criteria for NASH (on
a liver biopsy) and completed a minimum follow-up period of
40 months after surgery. Between January 2002 and December
2009, of the 84 patients with a NAS≥ 5 on the wedge-liver biopsy
at the time of surgery, 33 had a follow-up of <36 months, 13
were lost to follow-up and 29 refused to reiterate the biopsy. The
comparison of clinical and biochemical parameters of the nine
NASH patients with a second liver biopsy (Table 1) compared
with those corresponding to the 75 NASH patients without a
second liver biopsy (Table 2) showed no significant differences
regarding BMI (P = 0.2473), fasting glucose level (P = 0.177),
fasting insulin level (P = 0.311), HOMA-IR (P = 0.5976),
prevalence of type 2 diabetes (44 vs. 42.6% respectively), ALT
TABLE 1 | Patients’ clinical and biochemical parameters at baseline and
after a ≥ 40-month follow-up period (patients with paired liver biopsies).
T0 T ≥ 40 p
Number 9 9 ns
Time after surgery
(months) (median, Q1; Q3)
55 (44; 75)
BMI (kg/m2) (median, Q1;
Q3)
42.0 (38.7; 45.1) 27.1 (24.3; 31.8) 0.042
1 BMI (kg/m2) (median,
Q1; Q3)
−13.7 (−16.4; −9.5)
Fasting glucose (mmol/l)
(median, Q1; Q3)
7.3 (5.3; 9.0) 4.7 (3.8; 5.5) 0.031
Fasting insulin (mUI/l)
(median, Q1; Q3)
24.7 (18.0; 33.0) 11.8 (6.5; 19.2) 0.032
HOMA-IR (median, Q1;
Q3)
7.4 (3.5; 10.8) 1.9 (1.3; 3.5) 0.008
Diabetes (%) 4 (44) 0 (0) ns
Metabolic syndrome (%) 7 (77) 2 (22) ns
CRP (mg/dl) (median, Q1;
Q3)
7.7 (5.7; 9.6) 0.6 (0.4; 2.4) 0.004
T0, baseline; T≥ 40, after a≥ 40-month follow-up period. BMI, Body-mass index;∆ BMI,
Excess BMI loss; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; CRP,
C-reactive protein; ns, not significant; p, the Mann-Whitney test or Fisher’s exact test.
level (P = 0.4038) and CRP level (P = 0.1828). Overall, nine
women met all the criteria and accepted the second biopsy. In
addition, data from blood samples obtained from five morbidly
obese patients, included in the same prospective ongoing study
and who had no sign of NAFLD on liver histology (aged 37 ±
10 years; BMI 44 ± 3 kg/m2), from seven patients with biopsy-
proven severe hepatic steatosis (aged 34 ± 8 years; BMI 46 ± 8
kg/m2), and from seven patients with biopsy-provenNASH (aged
40± 8 years; BMI 41± 3 kg/m2) were used in this study.
Population Characteristics
All patients were negative for hepatitis B and C viral markers,
auto-antibodies indicative of autoimmune hepatitis, and had
self-reported negligible alcohol consumption (<20 g/day in
women and <30 g/day in men). Alcohol abuse was also
excluded by interviewing the patients’ relatives. Patients with a
history of inflammatory disease (including rheumatoid arthritis,
systemic lupus erythematosus, and inflammatory bowel disease),
current infections, recent history of cancer (<5 years), and
severe pulmonary or cardiac disease were not enrolled in the
study. The patients’ characteristics are described in Table 1.
Before surgery and during the follow-up (6, 12 months
and the last follow-up visit before the second liver biopsy),
fasting blood samples were obtained and analyzed for alanine
aminotransferase (ALT), glucose and insulin, triglycerides, high-
density lipoprotein (HDL)-cholesterol, C-reactive protein, and
caspase-generated keratin (K18 fragment). Metabolic syndrome
was defined according to the modified International Diabetes
Federation (IDF) criteria of three or more of the following:
(i) central obesity defined by an increased waist circumference
(≥80 cm), (ii) triglycerides ≥1.7 mmol/L or treatment for
hyper-triglyceridemia; (iii) HDL-cholesterol <1.29 mmol/L; (iv)
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TABLE 2 | Patients’ clinical and biochemical parameters at baseline and after a 12-month follow-up period (patients without a second liver biopsy).
T0 T0 T12 p
Number 75 30 30
Gender (F/M) 57/18 23/7
BMI (kg/m2) (median, Q1; Q3) 43.7 (40.2; 47.2) 45.5 (41.0; 48.6) 28.8 (25.5; 32.3) <0.001
1 BMI (kg/m2 ) (median, Q1; Q3) −15.1 (−19.9;−13.4)
Fasting glucose (mmol/l) (median, Q1; Q3) 5.5 (5.1; 7.4) 5.8 (5.1; 9.7) 4.7 (4.1; 5.2) <0.001
Fasting insulin (mUI/l) (median, Q1; Q3) 28.0 (18.0; 44.0) 27.0 (17.2; 39.5) 6.8 (4.9; 12.0) <0.001
HOMA-IR (median, Q1; Q3) 7.8 (4.8; 12.4) 7.6 (5.8; 11.3) 1.3 (1.0; 2.1) <0.001
Diabetes (%) 32 (42.6) 18(60) 4 (13.3) <0.001
Metabolic syndrome (%) 36 (48) 21 (70) 9 (30) 0.002
CRP (mg/dl) (median, Q1; Q3) 9.0 (6.0; 14.5) 9.0 (6.8; 14.5) 2.9 (1.1; 4.1) <0.001
ALT (IU/L) (median, Q1; Q3) 50.5 (36.0; 72.5) 53.5 (35.7; 69.5) 24.0 (18.0; 32.0) <0.001
NAS (grade) (median, Q1; Q3) 5.0 (5.0; 5.0) 5.0 (5.0; 5.0)
T0, baseline; T12, 12-month follow-up. BMI, Body-mass index; ∆ BMI, Excess BMI loss; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; CRP, C-reactive protein; ns,
not significant; p, the Mann-Whitney test or Fisher’s exact test.
systolic blood pressure ≥130 mmHg or diastolic blood pressure
≥85mmHg or treatment for hypertension, and (v) fasting plasma
glucose ≥5.6 mmol/L or previously diagnosed type-2 diabetes
mellitus (Alberti et al., 2006). Type-2 diabetes was defined
by two measurements of elevated fasting plasma glucose ≥7
mmol/L. Insulin resistance was evaluated using the homeostatic
model assessment (HOMA-IR) index (Wallace et al., 2004). Nine
patients (only women) with biopsy-proven NASH had liver
biopsies repeated at a median follow-up of 55 [44; 75] months
after surgery. The first liver biopsy was a wedge biopsy obtained at
the beginning of the LRYGB, with no ischemic preconditioning.
The second was a needle-biopsy of the liver, obtained using the
percutaneous approach. The quality of the biopsies of the nine
included patients was sufficient for interpretation and the length
of each liver biopsy was over 15 mm. It is however important to
underline the fact that potential limitations of comparing wedge
to needle biopsies exist. Biopsies were stained with hematoxylin–
eosin–saffron and sirius red. Liver biopsies were reviewed by two
liver pathologists who were blinded to the clinical and biological
characteristics of the patients. Histopathological analyses were
performed according to the scoring system of Kleiner et al.
(2005). Four histopathological features were semi-quantitatively
evaluated: grade of steatosis (0, <5%; 1, 5–33.3%; 2, >33.3–
66.6%; 3, >66.6%), lobular inflammation (0, no inflammatory
foci; 1,<2 inflammatory foci per 200x field; 2, 2–4 inflammatory
foci per 200x field; 3, >4 inflammatory foci per 200x field),
hepatocellular ballooning (0, none; 1, few balloon cells; 2, many
cells/prominent ballooning), and liver bridging fibrosis (classified
into seven stages according to the NASH Clinical Research
Network Scoring System Definition F0, no fibrosis; F1a, mild
zone 3 sinusoidal fibrosis; F1b, moderated zone 3 sinusoidal
fibrosis; F1c, peri-portal sinusoidal fibrosis; F2, zone 3 sinusoidal
fibrosis and peri-portal sinusoidal fibrosis; F3, bridging fibrosis;
and F4, cirrhosis). The NAFLD activity score (NAS) is defined
as the unweighted sum of scores for steatosis (0–3), lobular
inflammation (0–3), and ballooning (0–2), thus ranging from 0
to 8 (Kleiner et al., 2005).
Circulating Levels of Transaminases and
K18 Fragment
Plasma alanine aminotransferase (ALT) levels were determined
using an in vitro test with pyridoxal phosphate activation
on a Roche/Hitachi cobas c system (ALTPM, cobas, Meylan,
France). Keratin 18 (K18) is cleaved by the caspases during
apoptosis, generating soluble protein fragments. The M30
Apoptosense R© ELISA assay specifically measures apoptosis (the
caspase-generated K18 fragment, K18-Asp396). All samples were
analyzed in duplicate following the manufacturer’s instructions.
The within assay (WA% CV) variation was <10% and between
assay (BA% CV) variation was <10% for samples >100 U/L.
The minimum detectable concentration was 25 U/L. Keratins
are released into the circulation as protein complexes. These
complexes are remarkably stable during sample collection and
long-term storage. Furthermore, plasma/serum samples can be
exposed to repetitive freeze–thaw cycles without loss of activity
(Olofsson et al., 2007).
IHC Analysis
Immunostaining for cleaved caspase-3 (Asp175) was performed
using rabbit plolyclonal antibodies against amino-terminal
residues adjacent to (Asp175) in human caspase 3. Sections
measuring 2 µm were cut from each paraffin block and were
put to dry at 37◦C during 12 h. After deparaffinization and
rehydration, all sections were pretreated at pH 6 with Flex
TRS Low (PTLink DAKO, Glostrup, Denmark) during 20 min.
Endogenous peroxidase was blocked in 1% hydrogen peroxide
for 5 min (DAKO, Glostrup, Denmark) at room temperature.
After rinsing with phosphate buffered saline, the sections were
incubated with cleaved caspase-3 (Asp175) antibody (#9661,
Cell Signaling) for 20 min at room temperature. Then sections
were incubated with an appropriate secondary antibody from
the Envision flex/HRP kit (Dako, Glostrup, Denmark) for 20
min, at room temperature. Next, slides were incubated in PBS,
for 20 min, at room temperature, and then peroxidase activity
was detected by diaminobenzidinetetrahydrochloride for 8 min
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and used for visualization and haematoxylin (Dako, Glostrup,
Denmark) during 6 min for nuclear counterstaining.
Statistical Analyses
The statistical significances between the two study groups
were determined using the non-parametric Mann-Whitney test
and Fischer’s test. A P < 0.05 was considered statistically
significant. Quantitative variables are presented as their medians
(interquartile ranges).
RESULTS
The aim of this study was to investigate the potentially long-
lasting beneficial effects of LRYGB on obesity-related liver
complications. To this end, 84 morbidly patients with biopsy-
proven NASH diagnosed at time of bariatric surgery (LRYGB)
were studied. Of these, nine women with a median age of 51 [35;
59] years at the time of LRYGB had a second liver biopsy after
≥40 months of follow-up (Table 1).
LRYGB Improves the Metabolic Syndrome,
Type-2 Diabetes, and Systemic
Inflammation
We first evaluated the effects of LRYGB on weight loss, the
metabolic syndrome, type-2 diabetes and systemic inflammation
in our NASH patients with paired-liver biopsies. All patients lost
more than 50% of excess BMI and had a median loss of −13.7
[−16.4; −9.5] kg/m2 BMI points (Table 1). Insulin resistance,
as evaluated by the HOMA-IR, fasting insulin and glycaemia
were strongly improved after LRYGB, as shown in Table 1. Four
patients with type-2 diabetes before surgery were in remission
at the time of the follow-up. The metabolic syndrome was
diagnosed in seven patients at the time of the initial surgery
and persisted in only two patients by the end of the follow-
up. Chronic low-grade inflammation, as evaluated by C-reactive
protein, was also improved after LRYGB in all patients (Table 1).
The beneficial effect of LRYGB on the metabolic syndrome and
systemic inflammation could already occur 1 year after bariatric
surgery as previously reported (Mathurin et al., 2006; Anty et al.,
2008; Bertola et al., 2009). In line with this, the analysis of the
clinical and biochemical parameters at baseline and at 12 months
after LRYGB of 30 out of our 75 patients without second liver
biopsy also showed a significant improvement of fasting insulin,
glycaemia, HOMA-IR, metabolic syndrome, diabetes, and CRP
(Table 2).
LRYGB Improves Hepatic Steatosis,
Inflammation, and NAFLD Activity Score
(NAS) in All Patients, and Improves Hepatic
Fibrosis in a Large Majority
We then evaluated the effects of LRYGB on obesity-related
liver complications. Liver steatosis was evaluated as severe (S3,
>66.6% of hepatocytes) in all patients at the time of surgery.
On the second biopsy, steatosis was improved in all patients:
i.e., full correction in five patients (55.5%) and grade 1 (44.4
%) in four patients (Figures 1A, 2A). The correction of hepatic
FIGURE 1 | Liver histology analysis of two representative patients (P1
and P2) at baseline and ≥40-months after LRYGB. (A) Liver steatosis was
improved (HES staining, x40). (B) Ballooned hepatocytes and hepatic
inflammation, both present at baseline, were no longer present on the second
liver biopsy (HES staining, x40). (C) P1 had bridging fibrosis (F = 3), P2 had
zone three sinusoidal fibrosis and peri-portal sinusoidal fibrosis (F = 2). The
second liver biopsy showed a significant improvement in fibrosis (F = 0) in
both patients (Sirius red straining, x40). T0, baseline; T ≥ 40, after a
≥40-month follow-up period.
steatosis was associated with a more important loss of weight as
evaluated by percentage of initial body weight (39 ± 6 vs. 24 ±
3%, P= 0.02). Hepatic inflammation, present in all patients at the
time of the surgery, was no longer present on the second biopsy
in any patient (Figures 1B, 2B). Ballooned hepatocytes, another
hallmark of NASH and a marker of liver-cell degeneration, were
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FIGURE 2 | LRYGB in NASH patients improves hepatic steatosis and inflammation in all patients, and improves hepatic fibrosis in the large majority
after a median follow-up of 55 months. Nine morbidly obese patients with biopsy-proven NASH underwent LRYGB and had a second liver biopsy at a median
follow-up period of 55 [44; 75] months after surgery. From the paired liver biopsies, steatosis (A), inflammatory foci (B), hepatocellular ballooning (C), and fibrosis (E)
were evaluated. (D) The NAFLD activity score (NAS) was evaluated as described in Section Materials and Methods. Fibrosis was semi-quantitatively evaluated as
follows: 0, none; 1, perisinusoidal or periportal mild (1A); 2, moderate (1B); 3, portal/periportal (1C); 4, perisinusoidal and portal/periportal; 5, bridging fibrosis; 6,
cirrhosis. (N) = number of patients.
found in all liver biopsies at the time of surgery, but were no
longer present in the second liver biopsy in eight patients (88.8%;
Figures 1B, 2C). Only one patient still had ballooned hepatocytes
on the liver biopsy in spite of significant weight loss, improved
metabolic syndrome, insulin resistance (HOMA-IR: from 5.4 to
2.3), hepatic steatosis (from S3 to S1) and hepatic inflammation
(Figure 2C). As a consequence, the NAS, which was elevated in
all patients at the time of surgery (eight patients with NAS =
5, and one with NAS = 6), dropped considerably in all patients
by 2–6 full points (Figure 2D). The stage of fibrosis was more
heterogeneous at the time of surgery, with only one patient
showing advanced fibrosis (F = 3), three patients with moderate
fibrosis (F = 2), four patients with mild fibrosis (1 with F = 1B, 3
with F= 1A) and one patient with no fibrosis (F= 0). The second
liver biopsy showed a significant improvement in fibrosis (F = 0)
in seven patients and a slight progression of liver fibrosis in one
patient (from F0 to F1A; Figures 1C, 2E). One patient without
fibrosis at the time of the surgery showed no signs of fibrosis on
the second biopsy. LRYGB was associated with corrected hepatic
steatosis and inflammation in all patients, and improvement of
fibrosis in 88.8% of patients.
LRYGB Improves Hepatic Injury and
Hepatocyte Apoptosis in All Patients
NASH is also characterized by the substantial death of
hepatocytes (Feldstein and Gores, 2005; Tran and Gual, 2013).
Hepatocyte apoptosis plays an important role in the progression
and the severity of obesity-related liver complications. We thus
investigated the long-term effect of LRYGB on hepatocyte injury.
ALT serum levels reached normal-range values in all patients
by the last follow-up (ALT: 38 [29; 74] to 24 [20; 26] UI/L;
Figure 3A). The serum levels of caspase-generated keratin 18
fragment (K18 fragment) were used to evaluate hepatocyte
apoptosis. An average decrease of 35% in serum K18 fragment
levels were found in 88.8% of patients after a median follow-up
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FIGURE 3 | LRYGB improves liver injury and hepatocyte apoptosis in NASH patients after a median follow-up of 55 months. Serum levels of (A) alanine
aminotransferase (ALT) and (B) a marker of hepatocyte apoptosis [caspase-generated keratin 18 fragment (K18 fragment)] and (D) hepatic levels of cleaved caspase
3 were evaluated at baseline and at the median follow-up of 55 [44; 75] months after LRYGB in NASH patients. The levels of K18 fragment were also evaluated (C) at
6 months and at 1 year after a LRYGB and, (E) at baseline (T0) and 1 year (T12) after LRYGB in three additional groups of patients without NAFLD (n = 5), severe
steatosis (n = 7), or NASH (n = 7). Results are expressed as the median [25th, 75th percentiles] (A,C,E).
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of 55 [44; 75] months after LRYGB (Figure 3B). One patient who
already had low serum K18 fragment levels at the time of the
LRYGB showed no significant changes (Figure 3B). Interestingly
in the initially NASH patients, the K18 fragment levels reached
those usually found in patients without hepatic complications
just 1 year after LRYGB (Anty et al., 2010; Lavallard et al.,
2011; Figure 3C). We then determined the hepatic caspase 3
activity, as evaluated by the cleaved caspase 3 (Asp175) levels
in the paired liver biopsies with a median follow-up of 55
[44; 75] months after LRYGB. As shown in Figure 3D, the
percentage of cleaved caspase 3 positive hepatocytes strongly
decreased (−40% average decrease) in all patients at the time of
follow-up. We also evaluated the K18 fragment levels in three
additional groups of morbidly obese patients without any signs
of NAFLD (n = 5), severe steatosis (n = 7), or severe steatosis
associated with NASH (n = 7): assessed from a liver biopsy at
baseline and at 1 year after LRYGB. While the K18 fragment
levels showed no significant difference in patients with hepatic
steatosis, they were increased in patients with NASH compared
with patients without NASH at the time of surgery (Figure 3E).
At 1 year after LRYGB, the levels of the K18 fragment had
strongly decreased in all NASH patients (Figure 3E). Altogether,
these data indicate that LRYGB had a beneficial effect on
hepatocyte apoptosis by 1 year post-surgery, and that this was
maintained for the median follow-up period of 55 [44; 75]
months.
DISCUSSION
While there is strong evidence for the beneficial effects of the
LRYGB on excess weight and resolution or reduction of type 2-
diabetes (with remission in 63.5% of cases; Ribaric et al., 2014),
its long term impact on liver histology in NASH patients needs to
be better characterized. Most studies with paired liver biopsies
reported a mean interval between LRYGB and a second liver
biopsy of 19 ± 4 (range: 12–25) months (Silverman et al., 1995;
Clark et al., 2005; Mattar et al., 2005; Mottin et al., 2005; Barker
et al., 2006; Csendes et al., 2006; Klein et al., 2006; Furuya et al.,
2007; Liu et al., 2007; Lassailly et al., 2013).
In this study, a second biopsy was performed on previously
morbidly obese patients with liver biopsy-proven severe steatosis
and NASH after a median interval of 55 [44; 75] months
after LRYGB. As reported herein and previously, 1 year after
surgery (Anty et al., 2008; Bertola et al., 2009; Ribaric et al.,
2014; Table 2), insulin resistance, the metabolic syndrome and
systemic inflammation had all improved. These positive effects
are thus maintained after a median follow-up period of 55
[44; 75] months. A beneficial impact of LRYGB on hepatic
steatosis was also observed in all of our patients, from total
resolution (in 55.6% of cases) to striking improvement (S3 to
S1: 44.4%). As previously reported, LRYGB already improved
hepatic steatosis, evaluated by paired liver biopsies, at a median
follow up of 18 [12; 23] months after LRYGB (Silverman et al.,
1995; Clark et al., 2005; Mattar et al., 2005; Mottin et al., 2005;
Barker et al., 2006; Klein et al., 2006; Furuya et al., 2007; Liu
et al., 2007). Furthermore, the improvement of hepatic steatosis
is not specific to a LRYGB procedure. A recent meta-analysis
compiled results from different bariatric procedures, including
LRYGB, gastric banding, sleeve gastrectomy, duodenal switch,
and biliopancreatic diversion and reported an improvement of
hepatic steatosis in 90% of cases (Chavez-Tapia et al., 2010).
Therefore, our study demonstrates that the beneficial impact of
LRYGB on insulin resistance, systemic inflammation, and hepatic
steatosis obtained 1 year after surgery is maintained for at least 40
months (median 55 [44; 75]).
Regarding the hepatic inflammation and fibrosis, some studies
with paired liver biopsies reported an improvement in the
histopathological criteria for NASH in the short term (mean
follow-up of 21.35 ± 4.5 months; Clark et al., 2005; Barker et al.,
2006; de Almeida et al., 2006) and fibrosis (Clark et al., 2005;
Mattar et al., 2005; Barker et al., 2006; Furuya et al., 2007) after
LRYGB surgery. In our study, a median follow-up period of 55
months after LRYGB exhibited beneficial effects on inflammatory
foci, ballooning and fibrosis. Our NASH patients showed 100%
improvement in inflammatory foci and 88.8% improvement in
ballooned hepatocytes after LRYGB surgery. As a consequence,
the NAS decreased in 100% of cases. Despite the heterogeneous
nature of the degree of hepatic fibrosis in our patients at the
time of LRYGB surgery, hepatic fibrosis improved in 88.8% of
cases. One patient showed a slight increase in fibrosis (from F0
to F1A). No explanation could be found concerning the patient
with no resolution of hepatocyte ballooning. Indeed, this patient
lost significant weight and had decreased metabolic syndrome
features, decreased insulin resistance (HOMA-IR: from 5.4
to 2.3) and improved ALT levels. Other liver complications
were also reduced, including hepatic steatosis (from S3 to S1),
inflammation and fibrosis (from F2 to F0). A recent report has
shown that the disappearance of NASH in nearly 85% of cases
and decreased pathological features of NAFLD already occur 1
year after the bariatric surgery in a cohort of 109 morbidly obese
patients with biopsy-proven NASH (Lassailly et al., 2015). The
beneficial effect of bariatric surgery (mainly LRYGB procedure)
on NASH could thus rapidly occur in the first year and be
maintained up to 40 months after the surgery.
We next found that hepatocyte apoptosis, as evaluated by the
serum K18 fragment had already improved 1 year after LRYGB
and remained low until the last follow-up (at 55 [44; 75] months).
This was also confirmed by a strong decrease in hepatic caspase
3 activity, as evaluated by the levels of hepatocyte cleaved caspase
3 for at least 40 months after LRYGB surgery. In our patients,
this serum hepatocyte apoptotic marker increased approximately
four-fold in patients with NASH, which is in accordance with
previous reports on overweight, obese and severely obese patients
(Wieckowska et al., 2006; Anty et al., 2008; Younossi et al., 2008;
Feldstein et al., 2009; Tamimi et al., 2011; Joka et al., 2012; Shen
et al., 2012), and correlates with NAS (r = 0.549, P < 0.001, n
= 41). However, it has been recently reported that K18 fragment
level could be inadequate as a screening test for staging NASH
according to its limited sensitivity (Cusi et al., 2014). In concert,
these data suggest that this non-invasive marker combined with
other clinical/laboratory parameters may be helpful to monitor
the evolution of NASH after bariatric surgery. Wai-Sun Wong
et al. recently reported that the levels of the serum K18 fragment
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reflected disease activity in a prospective longitudinal study on
overweight/obese patients undergoing paired liver biopsies with
a follow-up time of 3 years (Wong et al., 2010).
The improvement in hepatocyte death and reduction of
inflammation after LRYGB surgery could prevent the progression
of hepatic complications. Indeed, apoptotic hepatocytes are
engulfed by Kupffer cells, which results in activation and
inflammation. The activation of stellate cells by apoptotic bodies
or by TGFβ from activated Kupffer cells then leads to liver fibrosis
(Malhi andGores, 2008). Furthermore, a pan-caspase inhibitor or
an overexpression of the anti-apoptotic Bcl2 protein was shown
to reduce fibrosis in an animal model of NAFLD and fibrosis,
respectively (Mitchell et al., 2009; Witek et al., 2009).
Although, the main weakness of the present study lies in
the small size of the sample and the gender bias (only females
were included), the exhaustive preoperative and postoperative
work-up and the paired liver biopsies allowed for a complete
characterization of our patients with NASH. We were thus
able to demonstrate that the LRYGB surgery results in
the concomitant remission of systemic inflammation, insulin
resistance and NASH features (steatosis, inflammation, and
hepatocellular ballooning) in all patients at a median follow-up
of 55 months. We also found a rapid decrease in hepatocyte
apoptosis, as evaluated by serum levels of K18 fragment.
These results should be confirmed in additional studies with
a larger sample size and a longer follow-up (>6 years) to
better understand the molecular mechanisms that are involved
in the remission of obesity-related liver complications after
LRYGB surgery, as well as after other bariatric procedures
to determine if they could share these beneficial effects.
Because pharmacological therapy has only marginal and perhaps
clinically irrelevant effects on NASH and fibrosis (Ratziu,
2013), and in light of our results, the implications for the
protective effects of LRYGB surgery against the progression
of obesity-related liver complications may become particularly
relevant.
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